Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Omeros Corporation (OMER) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 449,760
  • Shares Outstanding, K 42,760
  • Annual Sales, $ 13,510 K
  • Annual Income, $ -75,100 K
  • 36-Month Beta 3.36
  • Price/Sales 31.93
  • Price/Book 0.00

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.83 +2.75%
on 12/08/16
14.15 -28.62%
on 11/15/16
-0.03 (-0.30%)
since 11/09/16
3-Month
7.20 +40.28%
on 10/18/16
14.15 -28.62%
on 11/15/16
-0.84 (-7.68%)
since 09/09/16
52-Week
7.20 +40.28%
on 10/18/16
16.80 -39.88%
on 03/10/16
-4.22 (-29.47%)
since 12/09/15

Most Recent Stories

More News
Omeros Extending Compassionate Use for Pediatric Patient No Longer Requiring Dialysis after OMS721 Treatment

Omeros Corporation (NASDAQ: OMER) today announced that, following physician request, it will provide continued supply of OMS721 for a pediatric patient with hematopoietic stem cell transplant-associated...

International Consortium of Complement Experts Receives EUR1.3 Million Grant to Study Role of MASP-2 and Lectin Pathway in Traumatic Brain Injury

Omeros Corporation (NASDAQ: OMER) today announced that an international consortium of complement experts from Italy, United Kingdom, Germany, Spain and Poland was awarded EUR1.3 million in...

Omeros Announces Successful Outcome of OMIDRIA(R) Pediatric Cataract Trial

Omeros Corporation (NASDAQ: OMER) today announced the successful outcome of its recently completed post-marketing clinical trial of the effect of OMIDRIA(R) (phenylephrine and ketorolac injection)...

How These Biotech Stocks are Faring? -- Alexion Pharma, Progenics Pharma, Omeros, and Chimerix

On Tuesday, all three benchmark US indices were trading positively at the close of the markets. The bullish trend was reflected by broad-based gains in the US markets which saw eight out of nine sectors...

Omeros Corp (OMER) in Focus: Stock Jumps 6.4% in Session

Omeros Corporation (OMER) was a big mover last session, as the company saw its shares rise over 6% on the day.

Single Dose of Omeros' Lead MASP-3 Inhibitor OMS906 Shows Multi-Week Blockade of the Alternative Pathway

Omeros Corporation (NASDAQ: OMER) today announced pharmacokinetic and pharmacodynamic data from the evaluation of OMS906 in non-human primates. OMS906 inhibits mannan-binding lectin-associated...

Omeros Corporation to Announce Third Quarter 2016 Financial Results on November 9, 2016

Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well...

Omeros Announces Completion of Initial Funding under $125 Million Credit Facility

Omeros Corporation (NASDAQ: OMER) today announced that it has completed the initial funding under its senior secured credit facility with affiliates of CRG LP, a healthcare-focused investment...

Omeros Files Orphan Drug Application for OMS721 in Immunoglobulin A Nephropathy

Omeros Corporation (NASDAQ: OMER) today announced that it has filed an application for orphan drug designation with the U.S. Food and Drug Administration (FDA) for OMS721 in the treatment...

Omeros Announces Positive Data from Phase 2 Clinical Trial Evaluating PPAR-Gamma Agonist in Heroin Users Treated with Buprenorphine/Naloxone

Omeros Corporation (NASDAQ: OMER) today announced positive results from a Phase 2 clinical trial evaluating the effects of a peroxisome proliferator-activated receptor (PPAR)-gamma agonist...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More

Business Summary

Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM)...

See More

Support & Resistance

2nd Resistance Point 10.85
1st Resistance Point 10.48
Last Price 10.10
1st Support Level 9.81
2nd Support Level 9.51

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.